爱得科技（920180.BJ）：国内脊柱类椎体成形系统龙头，受益人口老龄化

Investment Rating - The report assigns a rating of "Buy" for the company, indicating an expected price increase of over 15% compared to the benchmark index within 6-12 months [58]. Core Insights - The company, Aide Technology, is a leading domestic player in the spinal vertebral body shaping system, benefiting from the aging population and increasing demand for orthopedic medical devices [3][28]. - The orthopedic implant medical device industry is projected to reach a market size of 24.6 billion yuan in 2024, driven by the aging population and increasing treatment penetration rates [4][36]. - The company has established a comprehensive product matrix covering 132 products across various orthopedic fields, including spinal, trauma, and sports medicine [5][35]. Summary by Sections Market Data - Total share capital is 0.89 billion shares [1]. Financial Data - The company is expected to achieve revenues of 2.86 billion yuan, 2.62 billion yuan, 2.75 billion yuan, and 3.02 billion yuan from 2022 to 2025, with year-on-year growth rates of -4.11%, -8.22%, 4.87%, and 9.74% respectively [6][47]. - Net profit for the same period is projected to be 9327.94 million yuan, 6356.86 million yuan, 6713.05 million yuan, and 7775.27 million yuan, with growth rates of -0.21%, -31.85%, 5.60%, and 15.82% respectively [6][47]. Company Overview - Aide Technology focuses on the research, production, and sales of orthopedic consumables, including spinal, trauma, and sports medicine products [3][28]. - The company has been recognized as a national high-tech enterprise and has received various accolades, including "Jiangsu Province Specialized and Innovative Small and Medium Enterprises" [3][28]. Competitive Advantages - The company has a well-established national sales network and a deep communication mechanism with hospitals and orthopedic doctors, enhancing product recognition and market penetration [5][35]. - Aide Technology has obtained 108 patents, with a research and development investment ratio of 6.96% from 2022 to 2024, indicating a strong commitment to innovation [5][35]. Market Trends - The demand for orthopedic implants is driven by a high prevalence of osteoporosis and vertebral compression fractures among the elderly population, with over 32% of individuals aged 65 and above affected [4][36]. - The company is adapting to the normalized procurement policies by promoting non-procurement products, which have shown steady growth, partially offsetting the revenue decline from procurement products [47]. Valuation Analysis - The company's projected price-to-earnings (PE) ratio for 2024 is 13.50, which is at a discount compared to comparable companies in the industry, whose average PE is 57.78 [25][26].